US-based medical technology company TELA Bio has launched the larger sizes of its OviTex PRS reinforced tissue matrix product in the US.
OviTex PRS is a tissue-based device reinforced with polymer suture embroidery, specifically designed for plastic and reconstructive surgery.
The device is intended for implantation to strengthen soft tissue in patients with existing weaknesses requiring repair or reinforcement.
Supplied sterile and for single use, OviTex PRS is engineered for consistency in thickness, stretch, permeability, and handling, facilitating functional remodelling.
The expanded OviTex PRS tissue matrix portfolio will now include larger configurations, such as a 25 x 30cm oval and a 25cm diameter circle.
The new sizes are intended to reduce the need for multiple smaller pieces, potentially simplifying complex plastic and reconstructive procedures.
TELA Bio co-founder, president and CEO Antony Koblish said: “The introduction of larger OviTex PRS sizes aligns with evolving trends in plastic and reconstructive surgery and strengthens the breadth of our offering in this space.
“Since launching OviTex PRS in 2019, we have sold nearly 15,000 units, with year-over-year unit sales growth of 31% in 2024 alone.
“Plastic and reconstructive surgeons are increasingly seeking alternatives to cadaveric tissue, and this expansion reinforces our commitment to meet that demand.”
TELA Bio is focused on advancing soft-tissue reconstruction solutions through technologies that optimise clinical outcomes by preserving and restoring the patient’s own anatomy.
The company’s solutions are economically effective and leverage the patient’s natural healing response, reducing long-term exposure to permanent synthetic materials.
TELA Bio medical affairs and surgeon strategy vice president Howard Langstein said: “These new sizes directly address the needs expressed by our key opinion leaders and customers.
“By reducing the need for suturing multiple smaller pieces together, we aim to improve surgical efficiency and potentially reduce costs, enhancing the surgeon’s ability to reinforce larger soft-tissue challenges.”
